Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Teva Pharmaceutical Industries Limited American Depositary Shares
(NY:
TEVA
)
24.21
-0.07 (-0.29%)
Official Closing Price
Updated: 7:00 PM EST, Nov 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries Limited American Depositary Shares
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
30
31
Next >
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead
↗
April 08, 2024
Three highly successful billionaire money managers are paring down their respective stakes in artificial intelligence (AI) titan Nvidia and purchasing shares of six beaten-down value stocks.
Via
The Motley Fool
Topics
Artificial Intelligence
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
April 06, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
April 04, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
8 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
↗
March 08, 2024
Via
Benzinga
Beyond The Numbers: 8 Analysts Discuss Teva Pharmaceutical Indus Stock
↗
February 12, 2024
Via
Benzinga
3 No-Brainer Stocks to Buy With $600 Right Now
↗
April 03, 2024
A relatively modest amount of money can go a long way when it's put to work in top-tier businesses with abundant catalysts.
Via
The Motley Fool
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
April 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
↗
March 25, 2024
Raymond James Financial, Inc. (NYSE: RJF) is now valued more highly than JPMorgan Chase & Co. (NYSE: JPM), according to Jim Cramer.
Via
Benzinga
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
↗
March 21, 2024
GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid...
Via
Benzinga
The Generic Drugs Antitrust Case
↗
March 16, 2024
Imagine that in the market for generic drugs, a group of companies form a cartel to raise prices on the products controlled by their group. What pattern might you expect to see for the prices of...
Via
Talk Markets
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
↗
March 02, 2024
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...
Via
Talk Markets
Drug Maker Organon Stock Scores Relative Strength Upgrade
↗
February 28, 2024
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
Via
Investor's Business Daily
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
February 26, 2024
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
February 26, 2024
Via
Benzinga
Ethereum Price Predictions: Where Will the ETH Crypto Go After Retaking $3,000?
↗
February 26, 2024
Ethereum price predictions are a hot topic on Monday as crypto traders wonder where the token will go after surpassing $3,000.
Via
InvestorPlace
Jefferies Just Raised Its Price Target on Salesforce (CRM) Stock
↗
February 26, 2024
Salesforce stock is rising higher on Monday after CRM shares got an increased price target from Jefferies analysts this morning.
Via
InvestorPlace
TEVA Stock Pops 4% as Teva Receives FDA Approval
↗
February 26, 2024
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.
Via
InvestorPlace
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
↗
February 26, 2024
FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more.
Via
Benzinga
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
↗
February 26, 2024
U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday.
Via
Benzinga
Topics
Stocks
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
February 26, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
6 reasons to buy Teva Pharmaceuticals stock sooner than later
February 26, 2024
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why
Via
MarketBeat
Topics
Lawsuit
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
↗
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Teva Pharma CEO Dismisses Split Speculations Expects Significant Interest For Its API Business Divestiture: Report
↗
February 20, 2024
Teva Pharmaceutical Industries confirms unity and dispels split rumors. CEO Richard Francis emphasizes the synergy between generics and branded drugs.
Via
Benzinga
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
February 20, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
↗
February 12, 2024
Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts.
Via
Benzinga
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
↗
February 12, 2024
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.
Via
Benzinga
Topics
Stocks
Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday
↗
February 12, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
↗
February 08, 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.
Via
InvestorPlace
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
30
31
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.